NasdaqGS:BNTXBiotechs
BioNTech Advances Oncology Focus With BNT324 Trial And Leadership Shift
BioNTech has started a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer.
The company is moving further into oncology therapeutics beyond its vaccine portfolio.
BioNTech appointed Kylie Jimenez as Chief People Officer to support its shift toward a multi-product oncology business.
BioNTech, listed as NasdaqGS:BNTX, is trading at $116.77, with the share price up 22.6% over the past 30 days and 20.8% year to date. Returns over 1 year...